Results 11 to 20 of about 2,811,792 (409)

Angiotensin Receptor–Neprilysin Inhibition in Acute Myocardial Infarction

New England Journal of Medicine, 2021
BACKGROUND: In patients with symptomatic heart failure, sacubitril-valsartan has been found to reduce the risk of hospitalization and death from cardiovascular causes more effectively than an angiotensin-converting-enzyme inhibitor.
M. Pfeffer, B. Claggett, E. Lewis, C. Granger, L. Køber, A. Maggioni, D. Mann, J. McMurray, J. Rouleau, S. Solomon, P. Steg, O. Berwanger, M. Čikeš, C. D. De Pasquale, C. East, A. Fernandez, K. Jering, U. Landmesser, R. Mehran, B. Merkely, F. Vaghaiwalla Mody, M. Petrie, I. Petrov, M. Schou, M. Senni, David Sim, P. van der Meer, M. Lefkowitz, Yinong Zhou, J. Gong, E. Braunwald   +30 more
semanticscholar   +1 more source

Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target

Intensive Care Medicine, 2020
A novel infectious disease, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was detected in Wuhan, China, in December 2019. The disease (COVID-19) spread rapidly, reaching epidemic proportions in China, and has been found in 27 ...
Haibo Zhang, J. Penninger, Yimin Li, N. Zhong, Arthur S Slutsky   +4 more
semanticscholar   +1 more source

Angiotensin receptor blockers as tentative SARS‐CoV‐2 therapeutics

Drug development research (Print), 2020
At the time of writing this commentary (February 2020), the coronavirus COVID‐19 epidemic has already resulted in more fatalities compared with the SARS and MERS coronavirus epidemics combined. Therapeutics that may assist to contain its rapid spread and
D. Gurwitz
semanticscholar   +1 more source

Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality.

Journal of the American Medical Association (JAMA), 2020
Importance It has been hypothesized that angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) may make patients more susceptible to coronavirus disease 2019 (COVID-19) and to worse outcomes through upregulation of the ...
E. Fosbøl, J. Butt, L. Østergaard, C. Andersson, C. Selmer, K. Kragholm, M. Schou, M. Phelps, G. Gislason, T. Gerds, C. Torp‐Pedersen, L. Køber   +11 more
semanticscholar   +1 more source

Coronavirus Disease 2019 (COVID‐19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2020
recent study confirmed that respiratory syndrome uses severe acute respiratory syndrome coronavirus (SARS- CoV) angiotensin- converting enzyme 2 (ACE2) for ...
Junyi Guo, Zheng Huang, Li Lin, Jiagao Lv   +3 more
semanticscholar   +1 more source

Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19

Journal of Travel Medicine, 2020
Highlight Intravenous infusions of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in experimental animals increase the numbers of angiotensin-converting enzyme 2 (ACE2) receptors in the cardiopulmonary ...
J. Diaz
semanticscholar   +1 more source

Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19

Circulation Research, 2020
Supplemental Digital Content is available in the text. Rationale: Use of ACEIs (angiotensin-converting enzyme inhibitors) and ARBs (angiotensin II receptor blockers) is a major concern for clinicians treating coronavirus disease 2019 (COVID-19) in ...
Peng Zhang, Lihua Zhu, Jingjing Cai, Fang Lei, Juan-Juan Qin, Jing Xie, Ye Liu, Yan-Ci Zhao, Xuewei Huang, Lijin Lin, Meng Xia, Ming-Ming Chen, Xu Cheng, Xiao Zhang, D. Guo, Yuanyuan Peng, Yan‐Xiao Ji, J. Chen, Zhi‐Gang She, Yibin Wang, Qingbo Xu, Renfu Tan, Hai-tao Wang, Jun Lin, Pengcheng Luo, Shouzhi Fu, Hongbing Cai, P. Ye, B. Xiao, W. Mao, Liming Liu, You-qin Yan, Mingyu Liu, Manhua Chen, Xiao-Jing Zhang, Xinghuan Wang, R. Touyz, J. Xia, Bing-Hong Zhang, Xiaodong Huang, Yufeng Yuan, L. Rohit, Peter P. Liu, Hongliang Li   +43 more
semanticscholar   +1 more source

Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System

Circulation Research, 2020
ACE2 (angiotensin-converting enzyme 2) has a multiplicity of physiological roles that revolve around its trivalent function: a negative regulator of the renin-angiotensin system, facilitator of amino acid transport, and the severe acute respiratory ...
Mahmoud Gheblawi, Kaiming Wang, A. Viveiros, Quynh Nguyen, J. Zhong, A. Turner, M. Raizada, M. Grant, G. Oudit   +8 more
semanticscholar   +1 more source

Current and future use of angiotensin II receptor blockers in patients with COVID-19

Качественная клиническая практика, 2020
No scientific evidence for the negative influence of angiotensin II receptor blockers onto COVID-19 clinical course has been identified so far. Prescribing angiotensin II receptor blockers as COVID-19 pathogenetic therapy could only be considered within ...
A. V. Matveev, V. A. Otdelenov, D. A. Sychev   +2 more
doaj   +1 more source

Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?

Journal of Hypertension, 2020
DOI:10.1097/HJH.0000000000002450 T he novel coronavirus causing the COVID-19 pandemic, SARS-CoV-2, gains entry to pulmonary cells after binding to membrane ACE2 [1].
M. Esler, D. Esler
semanticscholar   +1 more source